Strategic Targeting Position TumorGen as a partner for larger biopharma players focused on metastasis targets by emphasizing access to a novel MCCC-targeting platform that could complement their pipelines and unlock new therapeutic spaces.

Affordability & Growth Highlight the company’s early-stage size and growing revenue to attract mid-to-large cap biotech firms seeking innovative platforms with scalable collaboration opportunities and potential for co-development deals.

Clinical Relevance Frame the MCCCs targeting platform as a differentiator for accelerating target discovery in cancer metastasis, aligning with partners pursuing precision oncology, liquid biopsy advancement, and metastatic disease interventions.

Tech & Integration Leverage TumorGen’s tech stack familiarity (Cloud, collaboration tools, and developer-friendly platforms) to propose integration-friendly partnerships, pilot projects, and data-enabled discovery programs with minimal on-site requirements.

Competitive Positioning Map to peer leaders in oncology genetics and diagnostics to identify collaboration or acquisition opportunities, suggesting co-marketing, licensing, or joint venture options to expand market reach.